Genmab — April 2019

E_L

SGEN had quarterly earnings yesterday and said a few words about Tisotumab. Nothing we don't know yet I think. transcript: https://seekingalpha.com/article/4256999-seattle-genetics-inc-sgen-ceo-clay-siegall-q1-2019-results-earnings-call-transcript?part=single

E_L

i'll post the main paragraph:

E_L

Tisotumab vedotin or TV is and ADC that we are developing in partnership with Genmab. We are conducting a pivotal Phase 2 single-arm single-agent trial for women with recurrent or metastatic cervical cancer which has recently completed enrollment and is designed to support a regular submission under the FDA's accelerated approval mechanism.

E_L

The primary endpoint of this trial is confirmed objective response rate by independent review. Updated data from the Phase 1 trial were recently reported at the Society of Gynecologic Oncology annual meeting showing a 22% confirmed objective response rate by independent review with a median duration of response of six months.

E_L

The safety profile of TV was as previously reported. We remain encouraged by the data in the setting where there is no standard of care and outcomes are poor.

E_L

We and Genmab are also evaluating TV in combination with other agents to inform our strategy of moving TV into earlier lines of cervical cancer. Further, we are enrolling patients in trials of TV with other solid tumors.

E_L

end quote

Bulder

Nice to hear that they have designed the trial for RTOR.

JohnW

Thanks E L. That was good news.

E_L

@Bulder yes, that shows good faith

JKY_VH

Tak E L

E_L

@Sukkeralf did you see BMS say anything about Humax IL8 in their earnings?

Sukkeralf

I havent looked but would guess not

bibob

God formiddag fra 10 km højde på vej sydpå. :-). Jeg kan se Genmab også lettede på vej nordpå. :-).

E_L

ok, just because you came with the links just after their earnings

E_L

Dr. Durie on Dara SC in the middle of the video
(again nothing we don't know...) https://www.youtube.com/watch?v=a8_MB7o0MZo

Sukkeralf

Bulder RTOR ?

Sukkeralf

From SG transcript: GSK has some fantastic data in multiple myeloma with the BCMA antibody drug conjugate. And what we hear from them is they're planning to submit in the second half of this year. And we're delighted through the impact in multiple myeloma. That is a potential large market. And they also are doing many other trials, including frontline. And so, that potentially could be a really big drug for GSK and really beneficial to patients and to Seattle genetics.

Solsen

Hvis GK er lige så dygtige til at arbejde med BCMA stoffet sim Ofatumumab er der intet at frygte.

Sukkeralf

(clinicaltrials.gov)